Correction: New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis

Khanna D, Huang S, Lin CJF, *et al.* New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. *Ann Rheum Dis* 2021;80:641–50. doi:10.1136/annrheumdis-2020-219100

The results section of the abstract should read: In the development sets (n=237), the proportion of participants in the active group had statistically higher improvement in ≥ 1 of 5 core set measures versus the placebo group. For example, the proportion who improved by $\geq 20\%$ in ≥ 3 core set measures was 49.4% in the active versus 38.9% in the placebo; RD: 10.5%, 95% CI 4.9% to 16.1%. In the validation sets (n=117), the proportion who improved by $\geq 20\%$ in ≥ 3 core set measures was 50.3% in the active versus 35.6% in the placebo (RD: 14.8%, 95% CI 3.1% to 25.7%). Similar trends were seen with larger percentage cut-offs.

The first sentence of the ‘Performance of five core set measures: development data sets’ section should read: The proportion of participants (n=237, development sets) who improved by $\geq 10\%$ to $\geq 60\%$ (in 5% increments) were numerically higher in the active therapy vs placebo group for all four core set measures mRSS, HAQ-DI, PGA and CGA and for FVC% at 5% and 10% relative improvement the majority of the time (table 3 and figure 1).

The third sentence of the ‘Performance of five core set measures: validation data sets’ section should read: The magnitude of the effects was comparable between the development and validation sets; for example, the proportion of participants who improved by $\geq 20\%$ in ≥ 1 core set measure was 92.7% in active therapy vs 80.1% in the placebo group, in ≥ 2 core set measures was 75.8% in active therapy vs 57.7% in the placebo group, in ≥ 3 core set measures was 50.3% in active therapy vs 35.6% in the placebo group and in ≥ 4 core set measures was 27.7% in active therapy vs 13.6% in the placebo group (table 4 and online supplemental figure 1).

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2021;80:e154. doi:10.1136/annrheumdis-2020-219100corr1